Leukæmi kliniske forsøg i Pennsylvania
15 studier for Leukæmi søger deltagere på steder i Pennsylvania.
Byer i Pennsylvania
Officiel studietekst (engelsk)
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
- Children's Hospital of Philadelphia, Philadelphia
RekruttererObservationsstudie
Alder 0 til 38 · Alle køn · Opdateret 1. okt. 2026 · NCT06131801A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
- University of Pennsylvania, Philadelphia
RekruttererFase 1/2
30 Days · Alle køn · Opdateret 16. sep. 2026 · NCT04065399Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
- Spoknwrd Clinical Trials Inc., Easton
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 16. sep. 2026 · NCT06824168Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
- Research Site, Pittsburgh
RekruttererFase 3
Alder 18 til 18 · Alle køn · Opdateret 8. sep. 2026 · NCT07509151First-in-human Study of a New Treatment (4A10) for Patients With Relapsed or Hard-to-treat Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma, Focused on Safety and How the Drug Behaves in the Body and Early Signs of Effect.
- Children's Hospital of Philadelphia, Philadelphia
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 1. sep. 2026 · NCT07586618Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
- University of Pennsylvania, Philadelphia
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 20. aug. 2026 · NCT07007312Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
- Children's Hospital of Philadelphia, Philadelphia
RekruttererFase 2
Alder 7 til 25 · Alle køn · Opdateret 19. aug. 2026 · NCT05082519Frailty Phenotype Assessments to Optimize Treatment Strategies for Older Patients With Hematologic Malignancies
- Abramson Cancer Center of the University of Pennsylvania, Philadelphia
RekruttererObservationsstudie
Alder 60 og opefter · Alle køn · Opdateret 12. aug. 2026 · NCT03680677CART123 Cells With or Without Ruxolitinib in Relapsed/Refractory Acute Myeloid Leukemia
- Children's Hospital of Philadelphia, Philadelphia
RekruttererFase 1
Alder 0 til 29 · Alle køn · Opdateret 7. jul. 2026 · NCT07464951A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
- Dren Investigational Site 2, Pittsburgh
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 17. jun. 2026 · NCT05475925Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
- Saint Christopher's Hospital for Children, Philadelphia
RekruttererObservationsstudie
Alle aldre · Alle køn · Opdateret 18. maj 2026 · NCT01790152Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCT
- Children's Hospital of Philadelphia, Philadelphia
RekruttererFase 1/2
1 Month – 25 Years · Alle køn · Opdateret 15. apr. 2026 · NCT06839456A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
- Hospital of the University of Pennsylvania, Philadelphia
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 13. mar. 2026 · NCT05735184Expanded Access Protocol Using CD3+/CD19+ Depleted PBSC
- Children's Hospital of Philadelphia, Philadelphia
RekruttererTidlig fase 1
Op til 30 år · Alle køn · Opdateret 20. feb. 2026 · NCT02356653SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Philadelphia
RekruttererObservationsstudie
Alle aldre · Alle køn · Opdateret 28. okt. 2025 · NCT03452774Fra ClinicalTrials.gov, data hentet 3. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.